Compare THRM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRM | IOVA |
|---|---|---|
| Founded | 1991 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 968.6M |
| IPO Year | 1993 | N/A |
| Metric | THRM | IOVA |
|---|---|---|
| Price | $37.43 | $2.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $39.00 | $10.45 |
| AVG Volume (30 Days) | 179.4K | ★ 10.2M |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $1,468,728,000.00 | $250,425,000.00 |
| Revenue This Year | $3.56 | $60.94 |
| Revenue Next Year | $2.52 | $60.85 |
| P/E Ratio | $37.73 | ★ N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $22.75 | $1.64 |
| 52 Week High | $41.09 | $8.15 |
| Indicator | THRM | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.09 | 57.57 |
| Support Level | $36.70 | $2.08 |
| Resistance Level | $38.06 | $2.60 |
| Average True Range (ATR) | 1.13 | 0.13 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 62.92 | 73.08 |
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.